CM512 vs lunsekimig

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: TSLP + IL-13 · full Atopic Dermatitis pipeline

CM512

Developed by Belenos Biosciences under a licence from Keymed Biosciences

Phase 2 in Atopic Dermatitisbispecific antibody
Weak signal

NCT06553209 · Phase 1 · completed

The study randomly assigned participants to active drug or matching placebo and blinded participants, care providers, investigators, and outcome assessors, which are the hallmarks of a well-controlled study. However, its only defined goal was tracking adverse events rather than any measure of skin-disease improvement. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Adverse events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: December 2027 · NCT07230483 (registry estimate)

Reported efficacy

Adverse events (Up to 141 days or up to 169 days): All treatment-related adverse events were Grade 1 or 2; no serious adverse events, no withdrawals for adverse events and no deaths. Pharmacokinetics were linear and dose-proportional from 150 to 1200 mg with a long terminal half-life (mean range 58.7 to 73.6 days). CM512 significantly reduced free TSLP and IL-13 and lowered blood eosinophils, IgE and TARC versus placebo.

Result source: NCT06553209

lunsekimig

Developed by Sanofi

Phase 2 in Atopic Dermatitisbiologic (Nanobody)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCM512lunsekimig
EASI-75—Not reported—Not reported
IGA 0/1 with 2-point improvement—Not reported—Not reported
EASI-90—Not reported—Not reported
EASI, % change—Not reported—Not reported

EASI-75

CM512
—Not reported
lunsekimig
—Not reported

IGA 0/1 with 2-point improvement

CM512
—Not reported
lunsekimig
—Not reported

EASI-90

CM512
—Not reported
lunsekimig
—Not reported

EASI, % change

CM512
—Not reported
lunsekimig
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

CM512: no structured comparison results are available for Atopic Dermatitis.

lunsekimig: no structured comparison results are available for Atopic Dermatitis.

Asthma

Shared mechanism: TSLP + IL-13 · full Asthma pipeline

CM512

Developed by Belenos Biosciences under a licence from Keymed Biosciences

Phase 2 in Asthmabispecific antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: July 2027 · NCT07011524 (registry estimate)

No aligned efficacy figure on record for this race.

lunsekimig

Developed by Sanofi

Phase 2 in Asthmabiologic (Nanobody)
Weak signal

NCT05366764 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Number of participants with adverse events (AEs) /TEAEs". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: June 2027 · NCT06676319 (registry estimate)

Reported efficacy

Number of participants with adverse events (AEs) /TEAEs (From baseline up to Day 71): Well tolerated in healthy volunteers, with COVID-19, nasopharyngitis, injection site reactions and headache the common treatment-emergent adverse events. Exposure increased dose-proportionally with linear elimination, mean terminal half-life was around 10 days across all IV and subcutaneous doses, and absolute bioavailability after a single 400 mg subcutaneous dose was 54%.

Result source: NCT05366764

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCM512lunsekimig
Severe exacerbations, annualised rate—Not reported—Not reported
Trough FEV1, change—Not reported—Not reported
ACQ-5, change—Not reported—Not reported
OCS dose reduction—Not reported—Not reported

Severe exacerbations, annualised rate

CM512
—Not reported
lunsekimig
—Not reported

Trough FEV1, change

CM512
—Not reported
lunsekimig
—Not reported

ACQ-5, change

CM512
—Not reported
lunsekimig
—Not reported

OCS dose reduction

CM512
—Not reported
lunsekimig
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

CM512: no structured comparison results are available for Asthma.

lunsekimig: no structured comparison results are available for Asthma.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CM512's landscape · lunsekimig's landscape